RAMM Pharma Corp Performance
The firm holds a Beta of 0.0, which implies not very significant fluctuations relative to the market. the returns on MARKET and RAMM Pharma are completely uncorrelated.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days RAMM Pharma Corp has generated negative risk-adjusted returns adding no value to investors with long positions. Despite nearly stable primary indicators, RAMM Pharma is not utilizing all of its potentials. The current stock price disturbance, may contribute to mid-run losses for the stockholders. ...more
| Begin Period Cash Flow | 28 M | |
| Total Cashflows From Investing Activities | -6.8 M | |
| Free Cash Flow | -4.2 M |
RAMM |
RAMM Pharma Relative Risk vs. Return Landscape
If you would invest (100.00) in RAMM Pharma Corp on December 22, 2024 and sell it today you would earn a total of 100.00 from holding RAMM Pharma Corp or generate -100.0% return on investment over 90 days. RAMM Pharma Corp is currently producing negative expected returns and takes up 0.0% volatility of returns over 90 trading days. Put another way, 0% of traded pink sheets are less volatile than RAMM, and 99% of all traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
RAMM Pharma Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for RAMM Pharma's investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as RAMM Pharma Corp, and traders can use it to determine the average amount a RAMM Pharma's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| RAMMF |
Based on monthly moving average RAMM Pharma is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of RAMM Pharma by adding RAMM Pharma to a well-diversified portfolio.
RAMM Pharma Fundamentals Growth
RAMM Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of RAMM Pharma, and RAMM Pharma fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on RAMM Pink Sheet performance.
| Return On Equity | -0.12 | |||
| Return On Asset | -0.0789 | |||
| Profit Margin | (1.76) % | |||
| Operating Margin | (1.89) % | |||
| Current Valuation | 1.85 M | |||
| Shares Outstanding | 122.4 M | |||
| Price To Book | 0.18 X | |||
| Price To Sales | 4.04 X | |||
| Revenue | 4.12 M | |||
| EBITDA | (6.36 M) | |||
| Cash And Equivalents | 12.79 M | |||
| Cash Per Share | 0.10 X | |||
| Total Debt | 8.69 K | |||
| Book Value Per Share | 0.41 X | |||
| Cash Flow From Operations | (3.82 M) | |||
| Earnings Per Share | (0.05) X | |||
| Total Asset | 59.71 M | |||
Things to note about RAMM Pharma Corp performance evaluation
Checking the ongoing alerts about RAMM Pharma for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for RAMM Pharma Corp help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| RAMM Pharma Corp is not yet fully synchronised with the market data | |
| RAMM Pharma Corp has some characteristics of a very speculative penny stock | |
| RAMM Pharma Corp has a very high chance of going through financial distress in the upcoming years | |
| The company reported the revenue of 4.12 M. Net Loss for the year was (7.11 M) with loss before overhead, payroll, taxes, and interest of (37.32 K). | |
| RAMM Pharma Corp has accumulated about 12.79 M in cash with (3.82 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.1. | |
| Roughly 35.0% of the company outstanding shares are owned by corporate insiders |
- Analyzing RAMM Pharma's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether RAMM Pharma's stock is overvalued or undervalued compared to its peers.
- Examining RAMM Pharma's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating RAMM Pharma's management team can have a significant impact on its success or failure. Reviewing the track record and experience of RAMM Pharma's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of RAMM Pharma's pink sheet. These opinions can provide insight into RAMM Pharma's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. You can also try the Money Flow Index module to determine momentum by analyzing Money Flow Index and other technical indicators.
Other Consideration for investing in RAMM Pink Sheet
If you are still planning to invest in RAMM Pharma Corp check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the RAMM Pharma's history and understand the potential risks before investing.
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios |